Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

Acquired Thrombotic Thrombocytopenic Purpura Clinical Trial

Official title:
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)

Status Completed

Clinical Trial Summary

The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Acquired Thrombotic Thrombocytopenic Purpura
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombotic Thrombocytopenic

Clinical Trial Details

NCT number	NCT02878603
Study type	Interventional
Source	Sanofi
Contact
Status	Completed
Phase	Phase 3
Start date	October 6, 2016
Completion date	October 23, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05876221` - Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
Recruiting	`NCT05046717` - Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura
Completed	`NCT02553317` - Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura	Phase 3
Recruiting	`NCT04985318` - Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP
Not yet recruiting	`NCT04021173` - A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)	Phase 2
Completed	`NCT01151423` - Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)	Phase 2